Oncolytics Biotech® Unveils Promising Clinical Results for Pelareorep in Metastatic Colorectal Cancer Treatment Strategy

Oncolytics Biotech® Unveils Promising Clinical Data for Pelareorep in Fighting Metastatic Colorectal Cancer

Oncolytics Biotech® Inc. (NASDAQ: ONCY), a clinical-stage immunotherapy firm, has recently provided updates on their drug, pelareorep, spotlighting its robust clinical data aimed at metastatic colorectal cancer (mCRC). These findings are particularly critical in the light of traditional treatment challenges, showcasing pelareorep's potential in survival and immune activation.

Oncolytics’ latest studies highlight remarkable efficacy and safety outcomes for pelareorep in combination treatments, specifically addressing patients with KRAS mutant mCRC. The data derived from several clinical trials point towards a significant survival advantage when pelareorep is utilized alongside established treatments.

In the pivotal REO 022 trial, the results for patients with platinum-refractory 2L KRAS mutant mCRC were striking. Participants treated with pelareorep combined with FOLFIRI and bevacizumab recorded a median progression-free survival (PFS) of 16.6 months. In contrast, those receiving the standard 2L regimen experienced a mere 5.7 months. This data highlights a nearly threefold increase in PFS, an impressive boost that underscores pelareorep's potential in significantly improving patient outcomes. Moreover, the median overall survival (OS) also demonstrated favorable results, soaring to 27.0 months compared to 11.2 months in the standard therapy cohort.

Further data compiled from the GOBLET study indicated that, in the 3L mCRC Cohort 3, pelareorep, when paired with atezolizumab and TAS-102, not only met its predetermined efficacy objectives but also prolonged survival, outperforming historical benchmarks for 3L mCRC treatment. This demonstrates the promising, multifaceted role that pelareorep could play in treatment regimens for advanced colorectal cancer.

Additionally, immunological studies conducted as part of the REO 013 study indicated robust immune system activation. Analyses showed that pelareorep facilitated viral replication within mCRC tumors, triggering immune responses such as dendritic cell maturation and activating CD8+ T cells. This hints at its ability to transform